ev3 humanitarian device
This article was originally published in The Gray Sheet
Executive Summary
FDA grants ev3 a humanitarian device exemption April 16 for its Onyx HD 500 liquid embolic system to treat wide-necked brain aneurysms. Launch to a small group of neurovascular specialists will follow a lengthy training period. The device is more viscous than ev3's Onyx 18 and 34 products, approved via PMA in 2005 for pre-surgical treatment of brain arteriovenous malformations (1"The Gray Sheet" July 25, 2005, In Brief). The HDE, which allows for treatment of up to 4,000 patients each year, was based on U.S. and European studies of more than 200 patients that would be less effectively treated with embolic coils...
You may also be interested in...
Onyx LES approved
Micro Therapeutics, Inc., a subsidiary of ev3, launches Onyx LES liquid embolic system for treating brain arteriovenous malformations (AVMs) following long-awaited PMA approval, announced July 21. The firm expanded its salesforce to 15 U.S. reps at the end of 2004 in anticipation of an early 2005 approval. The system is indicated for the pre-surgical embolization of brain AVMs, which reduces the size and vascularity of the AVM, making it easier to surgically resection, the company explains (1"The Gray Sheet" Feb. 28, 2005, p. 24)...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.